Navigation Links
Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting

tential enhancement to cancer vaccines. In a challenging model of aggressive brain cancer, 57% of animals immunized with a bavituximab equivalent and irradiated, inactivated tumor cells achieved long-term survival compared to 0% in untreated animals and only 16% survival in animals receiving inactive tumor cells with an antibody that does not block PS. To achieve this survival result, the vaccine-like bavituximab regimen is estimated to have enabled these animals to destroy 99.99% or more of the huge tumor cell challenge they were given. These impressive results provide important confirmation of the ability of bavituximab's anti-PS mechanism to reverse the immune system inhibition caused by cancer and offer another potential application for bavituximab and Peregrine's other anti-PS antibodies. * Data demonstrating the potent anti-cancer efficacy of bavituximab in combination with chemotherapy. A bavituximab equivalent in combination with the common cancer chemotherapy docetaxel reduced the growth of both hormone-dependent and hormone-independent prostate cancer by up to 94%. Bavituximab is currently being assessed in a Phase lb cancer clinical trial that includes patients receiving docetaxel. Prostate cancer is one of the most common cancers affecting men and is a leading cause of cancer deaths. * Data supporting use of anti-PS antibodies as the targeting agent for immunocytokine fusion proteins based on Peregrine's VTA platform. Their ability to target phospholipids primarily expressed on the surface of tumor blood vessels enables bavituximab-like antibodies to also serve as targeting agents for Peregrine's Vascular Targeting Agent (VTA) technology platform. Studies presented at AACR assessed the anti-cancer properties of VTA-based immunocytokine fu
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
4. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
5. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/24/2014)... KENNEWICK, Wash. , Dec. 23, 2014 /PRNewswire/ ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that it has ... the Food and Drug Administration ("FDA") for marketing ... to Section 513(f)(2) of the U.S. Food, Drug ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... 2011 ArjoHuntleigh, Inc. is pleased to announce ... Compression Devices with HealthTrust Purchasing Group, L.P. (HealthTrust). ... members to take advantage of special pricing and ... (IPC) devices for the prevention of deep vein ...
... Ltd, a leading source for life science sector analysis and ... sales, revealed today that Sanofi is expected to take the ... hold it through 2016. The French drug maker has raced ... activity, with the $20bn purchase this year of US biotechnology ...
Cached Medicine Technology:ArjoHuntleigh Awarded Vascular Compression Contract With HealthTrust Purchasing Group 2Sanofi Tops Pfizer as Number One for Global Pharma Sales 2
(Date:12/26/2014)... AZ (PRWEB) December 26, 2014 ... source for the best in heating, cooling and ... for 24 hour emergency services in 2014 with ... alike know that Arizona is known for its ... company that understands the intricacies and details of ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, LunaDress.co.uk has updated ... dresses and related accessories. Now, all of the models at LunaDress.co.uk ... moment a groom lifts the wedding veil can turn out to ... stunning charm. A wedding veil can always bring surprise to a ... suggestions on how to choose veils for a big day ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... HOLX ) today announced that Patrick Sullivan, Executive ... at the Lehman,Brothers Eleventh Annual Global Healthcare Conference being ... Miami, Florida., Interested parties are invited to listen ... Thursday, March 20, at 10:15 a.m.,Eastern Time on the ...
... German . , Scientists at the ... of haemo-globin. Haemoglobin transports oxygen in the red blood ... new haemoglobin type appears optically to be transporting little ... a similar picture to patients suffering from an inherited ...
... ENGLEWOOD, Colo., March 17 Baxa Corporation ... Training, Academics and Resources),Center course offerings. Safe ... developed for nurses, pharmacists and physicians that ... course combines hands-on,experience with regulatory compliance and ...
... to new drugs to check vascular proliferation that is ... (HealthDay News) -- Researchers have pinpointed a biological pathway ... behind most cases of blindness in the United States. ... suggests a new therapeutic target for such ophthalmic diseases ...
... CARMEL, Ind., March 17 Conseco, Inc. (NYSE:,CNO) today ... Partners II,L.P. to nominate two of its representatives to ... been reviewing strategic,alternatives and has engaged the investment banking ... CEO Jim Prieur said, "We share with Steel Partners, ...
... Inc.,(Nasdaq: ANSS ), a global innovator of ... processes, today announced it is a,sponsor of the ... Museum of,Natural History in Pittsburgh. This is the ... accurate, immersive environments that are,composed of original fossil ...
Cached Medicine News:Health News:Hologic to Present at Lehman Brothers Healthcare Conference 2Health News:Bonn scientists discover new hemoglobin type 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 3Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 2Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: